Fibrillation properties of human α1-acid glycoprotein

被引:14
|
作者
Scire, Andrea [1 ]
Baldassarre, Maurizio [1 ]
Galeazzi, Roberta [1 ]
Tanfani, Fabio [1 ]
机构
[1] Univ Politecn Marche, Dipartimento Sci Vita & Ambiente, I-60131 Ancona, Italy
关键词
alpha(1)-Acid glycoprotein; Orosomucoid; Protein aggregation; Amyloid-like fibrils; Nanostructures; BOVINE SERUM-ALBUMIN; FORMATION IN-VITRO; ALPHA-1-ACID GLYCOPROTEIN; AMYLOID FIBRILS; AGGREGATION; PROTEIN; MECHANISM; BINDING; TRANSTHYRETIN; OLIGOMERS;
D O I
10.1016/j.biochi.2012.09.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human alpha(1)-acid glycoprotein (AGP) is a positive acute phase plasma protein containing two disulfide bridges. Structural studies have shown that under specific conditions AGP undergoes aggregation. In this study, we analysed the nature of AGP's aggregates formed under reducing and non-reducing conditions at pH 5.5 and at relatively low temperatures. Thioflavin T and Congo red spectroscopic analyses indicated the presence of cross-beta structures in both unreduced and reduced AGP aggregates. In these samples amyloid-like fibrils were detected by transmission electron microscopy. The fibrils are branched and bent and present in very large amount in reduced AGP. Kinetics of AGP fibrillation proceeds without a lag phase and the rate constants of cross-beta formation are linearly dependent on AGP concentration and result higher under reducing conditions. The data suggest a possible downhill mechanism of polymerization with a first-order monomer concentration dependence. Bioinformatics tools highlighted an extended region that sheathes one side of the molecule containing aggregation-prone regions. Reducing conditions make the extended region less constricted, allowing greater exposure of aggregation-prone regions, thus explaining the higher propensity of AGP to aggregate and fibrillate. (c) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:158 / 166
页数:9
相关论文
共 50 条
  • [1] Interaction of Aripiprazole With Human α1-Acid Glycoprotein
    Nishi, Koji
    Sakurama, Keiki
    Kobashigawa, Yoshihiro
    Morioka, Hiroshi
    Udo, Nagiko
    Hashimoto, Mai
    Imoto, Shuhei
    Yamasaki, Keishi
    Otagiri, Masaki
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (12) : 3911 - 3916
  • [2] Structure and function of human α1-acid glycoprotein
    Maruyama, Toru
    NIPPON SUISAN GAKKAISHI, 2015, 81 (04) : 731 - 731
  • [3] Anti-inflammatory properties of specific glycoforms of human α1-acid glycoprotein
    Van Dijk, W
    Poland, DCW
    GLYCOBIOLOGY AND MEDICINE, 2003, 535 : 251 - 256
  • [4] Characterization of Thymoquinone Binding to Human α1-Acid Glycoprotein
    Lupidi, Giulio
    Camaioni, Emidio
    Khalife, Hamal
    Avenali, Luca
    Damiani, Elisabetta
    Tanfani, Fabio
    Scire, Andrea
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (07) : 2564 - 2573
  • [5] α1-acid glycoprotein in shock
    Muchitsch, EM
    Pichler, L
    Schwarz, HP
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R113 - R113
  • [6] Importance of pH and disulfide bridges on the structural and binding properties of human α1-acid glycoprotein
    Scire, Andrea
    Baldassarre, Maurizio
    Lupidi, Giulio
    Tanfani, Fabio
    BIOCHIMIE, 2011, 93 (09) : 1529 - 1536
  • [7] Biliverdin is the endogenous ligand of human serum α1-acid glycoprotein
    Zsila, Ferenc
    Mady, Gyoergy
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (03) : 503 - 507
  • [8] Growth of viridans streptococci on human serum α1-acid glycoprotein
    Byers, HL
    Tarelli, E
    Homer, KA
    Hambley, H
    Beighton, D
    JOURNAL OF DENTAL RESEARCH, 1999, 78 (07) : 1370 - 1380
  • [9] Progesterone binding to the tryptophan residues of human α1-acid glycoprotein
    Albani, J. R.
    CARBOHYDRATE RESEARCH, 2006, 341 (15) : 2557 - 2564
  • [10] Contribution of the α1-Acid Glycoprotein in Drug Pharmacokinetics: The Usefulness of α1-Acid Glycoprotein-Knockout Mice
    Nakamura, Yuka
    Watanabe, Hiroshi
    Imafuku, Tadashi
    Fujita, Issei
    Ganaha, Yuto
    Takeo, Toru
    Nakagata, Naomi
    Maeda, Hitoshi
    Maruyama, Toru
    MOLECULAR PHARMACEUTICS, 2024, 21 (07) : 3144 - 3150